Skip to main content

Advertisement

Log in

Pelvic Lymph Node Dissection Is Beneficial in Subsets of Patients with Node-positive Melanoma

  • Melanomas
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The benefits of deep pelvic lymph node dissection (DLND) for patients with node-positive melanoma continue to be debated. The objective of our analysis was to identify factors associated with involvement of pelvic nodes and to determine survival outcomes following DLND.

Methods

We retrospectively reviewed the records of 804 patients who had undergone any type of lymph node dissection between 1990 and 2001. Logistic regression was performed to identify factors associated with tumor metastasis to pelvic nodes. Associations between clinicopathological factors and survival outcomes were estimated using the Cox proportional hazards model.

Results

Of the 804 patients, 235 underwent superficial lymph node dissection (SLND) and 97 underwent combined SLND and DLND (combined LND). Age ≥50 years, number of positive superficial nodes, and positive radiological imaging findings were found to be predictors of metastasis to deep nodes. With a median follow-up of 7.5 years, 5-year overall survival (OS) was 42% for patients with positive deep nodes and 51% for those with negative deep nodes (P = 0.11). OS in patients with melanoma that metastasized to three or fewer deep pelvic lymph nodes is comparable to that in patients with no deep nodal involvement. Multivariate analysis identified number of positive deep nodes, male gender, and extra-capsular extension as independent adverse prognostic factors for OS.

Conclusions

These relatively favorable survival outcomes support current surgical practice and the classification of metastatic pelvic nodal disease as stage-III rather than stage-IV (distant) disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

FIG. 1.
FIG. 2.
FIG. 3.

Similar content being viewed by others

References

  1. The NCCN GUIDELINE: Clinical Practice Guidelines in Oncology (Version 3.2005). © 2006 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed [March 6, 2007]

  2. Kubik S. Textbook of Lymphology. 1st edn. Elsevier GmbH, Munchen, 2003

    Google Scholar 

  3. Kretschmer L, Neumann C, Preusser KP, Marsch WC. Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin—an analysis of survival and local recurrence. Acta Oncol 2001; 40(1):72–78

    Article  PubMed  CAS  Google Scholar 

  4. Hughes TM, A’Hern RP, Thomas JM. Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma. Br J Surg 2000; 87(7):892–901

    Article  PubMed  CAS  Google Scholar 

  5. Mann GB, Coit DG. Does the extent of operation influence the prognosis in patients with melanoma metastatic to inguinal nodes? Ann Surg Oncol 1999; 6(3):263–271

    Article  PubMed  CAS  Google Scholar 

  6. Meyer T, Merkel S, Gohl J, Hohenberger W. Lymph node dissection for clinically evident lymph node metastases of malignant melanoma. Eur J Surg Oncol 2002; 28(4):424–430

    Article  PubMed  Google Scholar 

  7. Strobbe LJ, Jonk A, Hart AA, et al. Positive iliac and obturator nodes in melanoma: survival and prognostic factors. Ann Surg Oncol 1999; 6(3):255–262

    Article  PubMed  CAS  Google Scholar 

  8. Essner R, Scheri R, Kavanagh M, et al. Surgical management of the groin lymph nodes in melanoma in the era of sentinel lymph node dissection. Arch Surg 2006; 141(9):877–882

    Article  PubMed  Google Scholar 

  9. Karakousis CP, Driscoll DL, Rose B, Walsh DL. Groin dissection in malignant melanoma. Ann Surg Oncol 1994; 1(4):271–277

    Article  PubMed  CAS  Google Scholar 

  10. Coit DG, Brennan MF. Extent of lymph node dissection in melanoma of the trunk or lower extremity. Arch Surg 1989; 124(2):162–166

    PubMed  CAS  Google Scholar 

  11. McCarthy JG, Haagensen CD, Herter FP. The role of groin dissection in the management of melanoma of the lower extremity. Ann Surg 1974; 179(2):156–159

    Article  PubMed  CAS  Google Scholar 

  12. Jonk A, Kroon BB, Rumke P, et al. Results of radical dissection of the groin in patients with stage II melanoma and histologically proved metastases of the iliac or obturator lymph nodes, or both. Surg Gynecol Obstet 1988; 167(1):28–32

    PubMed  CAS  Google Scholar 

  13. Karakousis CP, Driscoll DL. Positive deep nodes in the groin and survival in malignant melanoma. Am J Surg 1996; 171(4):421–422

    Article  PubMed  CAS  Google Scholar 

  14. Ballo MT, Zagars GK, Gershenwald JE, et al. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol 2004; 11(12):1079–1084

    Article  PubMed  Google Scholar 

  15. Greene FL, American Joint Committee on Cancer, American Cancer Society. Chapter 24 Melanoma of the Skin. AJCC cancer staging handbook: from the AJCC cancer staging manual. Springer, New York, 2002: pp. 239

  16. Kaplan EL. Nonparametric estimator from incomplete observations. J Am Stat Assoc 1958; 53:457–481

    Article  Google Scholar 

  17. Cox DR. Regression models and life tables. J.R. Stat Soc 1972; B34:187–220

    Google Scholar 

  18. Therneau T.M, Grambsch PM. Modeling Survival Data: Extending the Cox Model. Springer, New York, 2000

    Google Scholar 

  19. Karakousis CP, Driscoll DL. Groin dissection in malignant melanoma. Br J Surg 1994; 81(12):1771–1774

    Article  PubMed  CAS  Google Scholar 

  20. Finck SJ, Giuliano AE, Mann BD, Morton DL. Results of ilioinguinal dissection for stage II melanoma. Ann Surg 1982; 196(2):180–186

    Article  PubMed  CAS  Google Scholar 

  21. Balch CM, Soong S-J, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004; 54(3):131–149

    Article  PubMed  Google Scholar 

  22. Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997; 15(3):1039–1051

    PubMed  CAS  Google Scholar 

  23. Buzaid AC, Tinoco LA, Jendiroba D, et al. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol 1995; 13(9):2361–2368

    PubMed  CAS  Google Scholar 

  24. Balch CM, Buzaid AC, Soong S-J, et al. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 2001; 19(16):3635–3648

    PubMed  CAS  Google Scholar 

  25. Balch CM, Soong S-J, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 2001; 19(16):3622–3634

    PubMed  CAS  Google Scholar 

  26. Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000; 7(2):87–97

    Article  PubMed  CAS  Google Scholar 

  27. Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000; 7(6):469–474

    Article  PubMed  CAS  Google Scholar 

  28. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17(3):976–983

    PubMed  CAS  Google Scholar 

  29. Gershenwald JE, Berman RS, Porter G, et al. Regional nodal basin control is not compromised by previous sentinel lymph node biopsy in patients with melanoma. Ann Surg Oncol 2000; 7(3):226–231

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We would like to acknowledge Beth Notzon for editorial assistance and Debbie Dunaway for manuscript preparation. This research was supported by NCI, Clinical Oncology Research Development Program, no. 5-K12-CA088084, and an ASCO Career Development Award, 88202.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Janice N. Cormier M.D., M.P.H..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Badgwell, B., Xing, Y., Gershenwald, J.E. et al. Pelvic Lymph Node Dissection Is Beneficial in Subsets of Patients with Node-positive Melanoma. Ann Surg Oncol 14, 2867–2875 (2007). https://doi.org/10.1245/s10434-007-9512-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-007-9512-7

Keywords

Navigation